The Podocyte in Diabetic Kidney Disease
Approaching epidemic levels, diabetic kidney disease (DKD) is now the leading cause of end-stage renal disease (ESRD). Microalbuminuria is an early clinical marker of DKD that results from damage to the glomerular filtration barrier at the level of the highly differentiated glomerular podocyte cells...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2009-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/tsw.2009.133 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524413821878272 |
|---|---|
| author | Erin Stitt-Cavanagh Laura MacLoed Chris R.J. Kennedy |
| author_facet | Erin Stitt-Cavanagh Laura MacLoed Chris R.J. Kennedy |
| author_sort | Erin Stitt-Cavanagh |
| collection | DOAJ |
| description | Approaching epidemic levels, diabetic kidney disease (DKD) is now the leading cause of end-stage renal disease (ESRD). Microalbuminuria is an early clinical marker of DKD that results from damage to the glomerular filtration barrier at the level of the highly differentiated glomerular podocyte cells. Injury to these epithelial cells, podocytopathies, includes cellular hypertrophy, foot process effacement, detachment from the glomerular basement membrane, and apoptosis. Here we review the role of a number of recently identified factors that contribute to podocytopathies in DKD. These factors include members of the renin-angiotensin system (RAS), including angiotensin-converting enzyme (ACE) types 1 and 2, prorenin and its receptor, reactive oxygen species (ROS), prostanoids, peroxisome proliferator-activated receptors (PPAR), advanced glycation end-products (AGEs) and their receptors (RAGE), adiponectin, and microRNAs. As the number of therapeutic options that slow, but do not halt, the progression of DKD to ESRD remains limited, a more comprehensive understanding of the signaling events that contribute to this increasingly prevalent disease may identify novel avenues for treatment and prevention. |
| format | Article |
| id | doaj-art-b6a872e9f8d74a1ca63e8e4ed3f62b80 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2009-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-b6a872e9f8d74a1ca63e8e4ed3f62b802025-02-03T05:53:22ZengWileyThe Scientific World Journal1537-744X2009-01-0191127113910.1100/tsw.2009.133The Podocyte in Diabetic Kidney DiseaseErin Stitt-Cavanagh0Laura MacLoed1Chris R.J. Kennedy2Kidney Research Centre, Chronic Disease Program, Ottawa Hospital Research Institute, CanadaKidney Research Centre, Chronic Disease Program, Ottawa Hospital Research Institute, CanadaKidney Research Centre, Chronic Disease Program, Ottawa Hospital Research Institute, CanadaApproaching epidemic levels, diabetic kidney disease (DKD) is now the leading cause of end-stage renal disease (ESRD). Microalbuminuria is an early clinical marker of DKD that results from damage to the glomerular filtration barrier at the level of the highly differentiated glomerular podocyte cells. Injury to these epithelial cells, podocytopathies, includes cellular hypertrophy, foot process effacement, detachment from the glomerular basement membrane, and apoptosis. Here we review the role of a number of recently identified factors that contribute to podocytopathies in DKD. These factors include members of the renin-angiotensin system (RAS), including angiotensin-converting enzyme (ACE) types 1 and 2, prorenin and its receptor, reactive oxygen species (ROS), prostanoids, peroxisome proliferator-activated receptors (PPAR), advanced glycation end-products (AGEs) and their receptors (RAGE), adiponectin, and microRNAs. As the number of therapeutic options that slow, but do not halt, the progression of DKD to ESRD remains limited, a more comprehensive understanding of the signaling events that contribute to this increasingly prevalent disease may identify novel avenues for treatment and prevention.http://dx.doi.org/10.1100/tsw.2009.133 |
| spellingShingle | Erin Stitt-Cavanagh Laura MacLoed Chris R.J. Kennedy The Podocyte in Diabetic Kidney Disease The Scientific World Journal |
| title | The Podocyte in Diabetic Kidney Disease |
| title_full | The Podocyte in Diabetic Kidney Disease |
| title_fullStr | The Podocyte in Diabetic Kidney Disease |
| title_full_unstemmed | The Podocyte in Diabetic Kidney Disease |
| title_short | The Podocyte in Diabetic Kidney Disease |
| title_sort | podocyte in diabetic kidney disease |
| url | http://dx.doi.org/10.1100/tsw.2009.133 |
| work_keys_str_mv | AT erinstittcavanagh thepodocyteindiabetickidneydisease AT lauramacloed thepodocyteindiabetickidneydisease AT chrisrjkennedy thepodocyteindiabetickidneydisease AT erinstittcavanagh podocyteindiabetickidneydisease AT lauramacloed podocyteindiabetickidneydisease AT chrisrjkennedy podocyteindiabetickidneydisease |